Publication Name	World Journal of Diabetes
Manuscript ID	47732
Country	Türkiye

Received	2019-03-22 00:17
Peer-Review Started	2019-03-22 08:15
To Make the First Decision	2019-06-03 02:41
Return for Revision	2019-06-03 06:14
Revised	2019-06-13 17:55
Second Decision	2019-06-17 08:41
Accepted by Journal Editor-in-Chief	2019-06-18 22:46
Accepted by Company Editor-in-Chief	2019-07-27 09:53
Articles in Press	2019-07-27 09:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-08-08 03:09
Publish the Manuscript Online	2019-08-15 14:56

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role in treatment; from the past to future
Manuscript Source	Unsolicited Manuscript
All Author List	Hakan Dogruel and Mustafa Kemal Balci
ORCID	Author(s) ORCID Number Hakan Dogruel http://orcid.org/0000-0002-6204-9796 Mustafa Kemal Balci http://orcid.org/0000-0002-6494-3249
Funding Agency and Grant Number
Corresponding Author	Hakan Dogruel, MD, Doctor, Department of Internal Medicine, Antalya Ataturk State Hospital, Anafartalar street. Number:100, Antalya 07001, Türkiye. dogruelhakan@gmail.com
Key Words	Incretin-based therapy; Incretin mimetics; Glucagon-like peptide-1 receptor agonist; Dipeptidyl peptidase-4 inhibitor; ;
Core Tip	The prevalence of type 2 diabetes and its complications rising dramatically over the last years. It is well known that diabetes and its complications; especially cardiovascular complications lead to increased morbidity and mortality. Treatment options for diabetes have increased as the pathophysiology was understood. We discuss the incretin-based therapy, especially Glucagon-like peptide-1 receptor agonists and the beneficial effects on comorbidities besides glucose lowering effect.
Publish Date	2019-08-15 14:56
Citation	Dogruel H, Balci MK. Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role in treatment; from the past to future. World J Diabetes 2019; 10(8): 446-453
URL	https://www.wjgnet.com/1948-9358/full/v10/i8/446.htm
DOI	https://dx.doi.org/10.4239/wjd.v10.i8.446

Full Article (PDF)	WJD-10-446.pdf
Full Article (Word)	WJD-10-446.docx
Manuscript File	47732-Review.docx
Answering Reviewers	47732-Answering reviewers.pdf
Audio Core Tip	47732-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	47732-Conflict-of-interest statement.pdf
Copyright License Agreement	47732-Copyright license agreement.pdf
Peer-review Report	47732-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	47732-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	47732-Scientific misconduct check.pdf
Scientific Editor Work List	47732-Scientific editor work list.pdf